Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.

Abstract excerpt

Imatinib mesylate (IM) trough concentration varies among IM-treated chronic myeloid leukemia (CML) patients. Although IM pharmacokinetics is influenced by several enzymes and transporters, little is known about the role of pharmacogenetic variation in IM metabolism. In this study, associations between IM trough concentration, clinical response and 11 single-nucleotide polymorphisms in genes involved in IM...

Topics

Join the communities discussing this publication.

• ATP Binding Cassette Transporter, Subfamily G, Member 2
• Benzamides
• Cytochrome P-450 CYP3A
• Imatinib Mesylate